Objectives: To gather benchmarking data on blood utilization so as to inform blood management strategies at regional hospitals. 
Spurred by the need to maximize patient safety as well as a drive to contain cost, 1,2 blood management has become increasingly important to blood bank managers, hospital administrators, and transfusion service physicians alike. The importance of rational blood use is not simply about economics: blood transfusion is a critical therapy, yet the risks, both infectious and noninfectious, are well described. [3] [4] [5] Moreover, conservative transfusion strategies have been met with equivalent or even superior outcomes (most notably a reduction in hospital mortality), which provides further motivation for considered transfusion practice. [6] [7] [8] [9] [10] A refined understanding of blood use can inform strategies that improve efficiency of product usage and can serve to minimize waste for the transfusion service. Knowledge of blood utilization also offers unique insight into clinical practice and can identify systemic deficiencies in patient care.
Blood management and optimization of use is a complex, multidisciplinary, and multiprofessional endeavor. 11, 12 Upon completion of this activity you will be able to:
• list the major reasons that underlie a need for conservative blood management.
• name at least two key metrics that can be used to audit blood utilization.
• list general transfusion triggers by component.
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The number of units transfused, even when stratified by component, is only one facet of utilization and alone is insufficient to inform development of a quality blood management system. Coupled with the myriad medical (eg, management of anemia) and surgical (eg, acute normovolemic hemodilution) approaches to blood conservation, 13 improved blood utilization requires a determination regarding appropriateness of use. This, in turn, requires an appreciation for the multiple processes that affect transfusion practice, which includes identification of the major end users (clinical disciplines) of blood and locations in which it is being transfused. More important, there needs to be an understanding as to how the decision to transfuse is being guided. This speaks to the presence of evidence-based transfusion guidelines and/or laboratory testing that support a given transfusion threshold. Ongoing monitoring of blood use is similarly important and encompasses the blood bank's auditing of blood product use as well as peer review of transfusions that do not conform to guidelines. Blood centers are increasingly tasked with the dual role as both the blood provider as well as the consultant to augment blood use. The blood center's expertise and guidance in this regard are particularly valuable to smaller hospitals that frequently lack resources that might otherwise be available in larger institutions. To serve our client hospitals, we developed an automated transfusion survey to evaluate the needs of our transfusion community.
Materials and Methods
The Blood Transfusion Practice Survey was designed with five sections: (1) General (demographics and scope of activity), (2) Hospital Blood Bank (number and type of blood product transfused, computer system, staffing, and point-ofcare testing), (3) Blood Bank Practices (pretransfusion testing and sample handling), (4) Blood Management (transfusion triggers, special component handling, and blood conservation measures), and (5) Blood Product Utilization Oversight (audits, accreditation, and blood ordering). Annualized data were requested. The survey was sent by standard mail to either the medical director or supervisor of transfusion services at each of the 40 hospitals served by the blood center at the time of the survey. Surveys were distributed and data collected from September 2009 through January 2010. Since this was survey was prepared and administered as part of operational procedures, human subjects approval was not required. Only aggregate data were collected, and no patientlevel data were reviewed.
Survey construction was done using TeleForm (HewlettPackard, Lake Forest, CA), a software program that enabled automated transcription of the completed survey directly into a database upon receipt from participating hospitals. Where respondent hospitals were part of larger health care systems, they were treated as individual institutions. Completed surveys were scanned and exported into an Excel (Microsoft, Redmond, WA) spreadsheet where the scanning process was validated by comparison of the written and scanned data; any errors were manually corrected. The validated and corrected data were then imported into Stata for analysis using version 11.2 or higher (StataCorp LP, College Station, TX).
The survey included screening questions for each component type to establish whether a transfusion trigger was in place at the respondent hospital. Follow-up questions surveyed the specific trigger using predefined categories (hemoglobin values of 7, 8-9, 10, or >10 g/dL for RBCs and platelet [PLT] counts of 5-10, 11-19, 20 , 50, or >50 ×10 9 /L for PLTs). Data on clinical settings in which specific thresholds were applied (eg, cardiac/pulmonary disease and uremia) were also collected. Triggers for fresh-frozen plasma (FFP) and cryoprecipitate (CRYO) transfusions were obtained using open-ended responses corresponding to the international normalized ratio (INR) or prothrombin time (relative to the midpoint of normal) for FFP and fibrinogen levels (mg/dL) for CRYO. Respondents were able to comment on triggers or clinical settings that were not included on the survey.
Data were reviewed in aggregate, and subsequently hospitals were grouped into tiers by number of beds as a proxy for hospital size, which allowed for data comparison by hospital size and complexity. Hospital size was stratified into very small (<100 beds), small (100-199 beds), medium (200-299 beds), and large (300-399 beds). Survey responses were analyzed descriptively, with comparison of proportions with c 2 statistics (using the Fisher exact test where appropriate) and comparison of means with the Student t test. One respondent hospital was omitted from the aggregate and stratified analyses because of the large disparity in hospital bed size and procedure type reported compared with the other respondents. This was done to ensure appropriate benchmarking of similar hospitals. Responses from participating institutions were kept confidential; individualized summary reports were created for each institution, and only aggregate results were presented to all respondents.
Results
Twenty-seven of 40 hospitals completed the survey for a return rate of 68%. Hospital size ranged from 23 to 600 beds, but the largest was removed from the analysis for reasons described above. ❚Table 1❚ provides the stratified summary of number of beds, average daily census, number and level of the trauma centers, and primary component usage. Results showed a wide range of transfusions for each component both within groups and overall (see Table 1 ). Annual RBC use ranged from a low of 46 units to a high of 8,950 units. Units of PLTs transfused varied widely as well (0-1,058), as did FFP (0-3,500 units) and CRYO (0-1,883 units). Interestingly, the highest number of units transfused was consistently found among the medium-size hospitals, except for plasma, which was highest in the large hospital group. However, the average daily census was also highest for medium-size hospitals and subsequently reflected in component usage. See ❚Figure 1❚ for the range of component use by hospital size.
Overall, 88.5% of hospital transfusion services had a computerized laboratory information system in place, but only 17% of equipped hospitals used its electronic cross-match (EXM) capability. Notably, no hospital in the large category used EXM. The percentage of hospitals with component-specific transfusion triggers was fairly consistent; 61.5% had RBC triggers, 57.7% had specific FFP triggers, 65.4% had PLT triggers, but only 46.2% had CRYO triggers, with one hospital not reporting. Details regarding specific triggers are provided in ❚Table 2❚. Specific hospital guidelines for a maximal surgical blood order schedule (MSBOS) and a massive transfusion protocol (MTP) were in place at 42.3% and 65.4% of all hospitals, respectively ❚Table 3❚. The number of units transfused was not significantly different between hospitals with component-specific triggers vs hospitals without triggers for any component. All respondent hospitals reported some type of blood product utilization oversight in place. Audits were directed at out-of-trigger transfusions (69%), rejected specimens (27%), transfusion reactions (81%), specific cross-match to transfusion ratios (62%), and general component wastage (73%) ( Table 3 ). The number of units transfused was not significantly different between hospitals that audited general wastage vs hospitals that did not for any component. ❚Figure 2❚ shows the percent component wastage as reported by all hospitals for RBCs, FFP, and PLTs. Blood utilization oversight was managed via transfusion committee review at 77% of reporting hospitals (Table 3) .
Where hospitals reported being part of a larger hospital system, we examined to what extent guidelines and practices differed within affiliations. A total of eight affiliations were reported, with six affiliations having two or more hospitals responding to the survey. Nineteen hospitals comprised the six affiliations. ❚Table 4❚ reports the proportion of affiliated hospitals with discordant component requirement policies, which ranged from 33% to 66%.
Discussion
There is a growing interest in blood management, which has largely been spurred by concern over the cost of excessive blood use allied with increased awareness of the potential adverse effects of blood transfusions. 2, 14, 15 This was foreseen as a timely opportunity to assist hospitals to identify areas of potential improvement with respect to their A B C blood use. Consequently, we conducted a pilot survey of 40 regional hospitals in Northern California, using a newly designed paper-based survey instrument. This survey-based study was conceived as a cross-sectional overview of regional transfusion infrastructure and clinical practices to capture baseline data, which might inform a comprehensive, follow-up, on-site evaluation. Twenty-seven of the 40 hospitals responded to our survey. The respondent hospitals were categorized into very small, small, medium, and large institutions according to their respective bed numbers, with a similar number of hospitals in each of the four categories (see Table 1 ). While not entirely unexpected, the average daily census was the primary determinant of RBC use. In contrast, the number of beds was most closely associated with PLT, plasma, and CRYO use, which could suggest increased complexity among the patient population in larger hospitals.
Less than two-thirds of hospitals reported transfusion triggers for RBCs. Implementation of guidelines with thresholds for RBC transfusion facilitates auditing of utilization and wastage. Guidelines can also help to identify aberrant transfusion practice. While the optimal threshold for RBC transfusion is still under debate, there is good evidence to suggest favorable morbidity and mortality outcomes with restrictive transfusion thresholds (ie, hemoglobin level of 7-8 g/dL) in most patients. 16, 17 The evidence for higher transfusion thresholds (eg, in patients with cardiovascular disease) is conflicted and merits further study. 17 In our study, nearly one-third of the hospitals reported not having PLT transfusion triggers. Platelets, a clinical necessity in selected patient populations, incur a major cost to the hospital. Evidence-based PLT transfusion guidelines are an effective method to ensure rational transfusion, balancing risk of withholding treatment (eg, bleeding) vs risk of unnecessary or inappropriate transfusion (eg, alloimmunization, transfusion-related acute lung injury
[TRALI], septic reactions). Spontaneous bleeding is unlikely in stable patients with PLT counts greater than 6 × 10 3 /µL. [18] [19] [20] [21] Given that most PLTs are transfused prophylactically rather than therapeutically, PLT counts less than 10 × 10 3 /µL should be well tolerated in the absence of active bleeding, fever, or sepsis. In addition to the clinical benefits, guidelines offer a cost-saving strategy for the blood bank through curbing inappropriate use. At the very least, the potential censure offered by a transfusion committee for unwarranted transfusions may reform practice. Furthermore, while less visible to end users, most PLTs in the United States are collected through apheresis, a process that imposes a burden on blood donors who are recruited specifically for this task. This underscores the need to transfuse per guidelines.
Plasma usage similarly incurs significant cost to the hospital. However, unlike thrombocytopenia, for which bleeding risk has been defined, 19, 20, 22, 23 plasma is frequently transfused with no clear benefit. 24, 25 Approximately 40% of hospitals in our study reported not having plasma triggers in place. Of the subset that did report transfusion triggers, seven hospitals reported a plasma trigger for an INR of 1.5 or less. The latter was reported, despite evidence that there is no correlation between bleeding risk and an INR below 1.7. 26 Independent of the financial ramifications of inappropriate transfusion, plasma transfusion places patients at risk of TRALI, which remains the leading cause of transfusion-associated mortality in the United States. 27 This has spurred broad implementation of TRALI mitigation strategies, which include exclusive collection of plasma from male donors. 28, 29 While there were too few hospitals in each category using a specific transfusion trigger to allow for meaningful statistical comparison, the findings do suggest that smaller hospitals are less inclined to have specific transfusion triggers in place for each of the component types ( Table 2) .
The survey also helped to evaluate transfusion practices. The overwhelming majority of respondent hospitals reported a laboratory information system (LIS) in place. Nearly threefourths of those same hospitals reported not using EXM, despite the ability for their individual LIS to accommodate the EXM, a tool that readily improves workflow and efficiency. 30 The EXM avoids unnecessary testing and thereby minimizes human error, while reagents, supplies, and labor costs are reduced.
Another high-yield focus was the auditing of wastage: more than one-fourth of respondent hospitals reported not auditing their component wastage, a critical baseline measure of utilization. Without data on ordering, product expiration, and discard, it is difficult to implement change. Although most hospitals reported some level of auditing, there was variability in practice with respect to monitoring of the key hospital (eg, an active hematology or trauma service). However, it could plausibly also reflect a less restrictive transfusion practice that would benefit from education surrounding use of transfusion triggers. We therefore refined our recommendations and provided several explanations that might explain the individual findings. While self-reporting is an acknowledged limitation, the survey was not intended to be an end unto itself; rather, it was used to guide on-site assessments, which were conducted at the client hospitals in ensuing months. In summary, each of the observations represents a potential area of intervention. We triaged our recommendations by importance and cost, recognizing that high-yield, lowcost interventions were more likely to be incorporated successfully into practice. The EXM, PLT, and plasma transfusion triggers specifically are "low-hanging fruit" that should be universally implemented. Comprehensive auditing of product wastage, too, is essential if hospitals are to evaluate blood utilization at any level.
While we enquired about a broad array of bloodconserving measures, we reserved recommendation of resource-intensive measures for the more sophisticated, large-volume hospitals. One example of a blood conservation measure is point-of-care (POC) testing, which may be used to evaluate bleeding and concomitant transfusion risk. 37 Examples include POC activated clotting time and thromboelastography, which could help to guide a patient's plasma and PLT needs through timely diagnosis of PLT vs clotting factor abnormalities. A number of studies have attested to the benefits of POC-informed transfusion therapy 38, 39 ; however, the advantages of POC testing are less clear in meta-analysis. 40 The data summaries were communicated to the individual hospitals and were used to inform the on-site evaluations, thereby allowing for targeted improvement. We plan to monitor progress using follow-up surveys coupled with on-site evaluations in the future. Subsequent to completion of the survey, we have observed broad changes in policy that suggest a trend toward standardization of hospital practices. We anticipate greater transfusion oversight with refined focus on defensible evidence-based guidelines in the future. In conclusion, the blood center can assume an important role in blood utilization. This holds wideranging benefits, not least of which is the ability to optimize patient care, conserve a critical resource, and contain cost.
indices of wastage, including the cross-match to transfusion ratios and individual components.
Other findings that could serve to improve blood conservation include the presence of an MSBOS and MTP, a reported absence of which was reported in one-half and onethird of hospitals, respectively. The MSBOS, the preallocation of a defined number of blood products per surgical procedure performed at a given hospital, can ensure that adequate blood is available for a given surgical procedure. The MSBOS is drafted in consultation with the clinical team performing the procedure (eg, surgeon and anesthesiologist); it is therefore individually tailored for a given hospital and, ideally, is updated as practices evolve. There are both advantages and disadvantages to the MSBOS. 31, 32 Foremost, the inherent preparedness limits urgent requests for blood products, thereby avoiding delays, which could otherwise have a detrimental effect on patient care. The disadvantage of the MSBOS is the potential for wastage and unnecessary demands on blood bank personnel, if poorly constructed.
The MTP has similar advantages to the MSBOS: by either preallocating prescribed products for a given event or by assigning a minimal number of products, it alleviates the burden on the blood bank to procure products urgently while ensuring that those products are immediately available during the acute stabilization phase. While there is ongoing debate surrounding the optimal component ratio within a trauma pack, the MTP is recommended in the trauma setting. 33, 34 Many of the respondent hospitals still reported a requirement for cytomegalovirus (CMV)-negative products for selected patient populations, despite universal leukoreduction of blood components. It has been shown that there is not a significant difference in CMV transmission between leukoreduced blood and blood obtained from CMVseronegative donors. 35, 36 Of interest, the requirement for CMV-seronegative blood was not uniform even among affiliated hospitals (see Table 4 ), suggesting a lack of standardization in practice at the time of reporting.
Our study was not without limitations. First, deficiencies in the questionnaire may have accounted for missing and incomplete data in some key response areas (eg, evaluation of the cross-match to transfusion ratio). Second, the study was conceived as a pilot survey that relied on self-reporting rather than on-site evaluation. In this regard, it was not a true benchmarking exercise, which extracts data from a broad, diverse data source (eg, hospital billing systems or patient records) to measure true utilization. Several groups offer professional services to evaluate blood utilization and draw on proprietary blood utilization models to generate recommendations. Our reliance on self-reporting lends itself to a potential disconnect between paper and practice. For example, transfusion of more RBCs than expected for census could reflect the patient population typically encountered at a given
